Accessibility Menu
Daiichi Sankyo, logo

Daiichi Sankyo,(OTC) DSNKY

Market Cap$30.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+174%
5 Year-19%
1 Year-33%
1 Month+2%
$17.59
+4.21%
+0.71Today
Daiichi Sankyo, last closing stock price
MetricPriceDate
Last closeUSD 17.592026-08-19
Daiichi Sankyo, stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.12%USD 17.792026-08-12
1 month+1.5%USD 17.332026-07-20
3 month+5.7%USD 16.642026-05-21
Year to date-16.05%USD 20.952025-12-31
1 year-33.16%USD 26.322025-08-19
3 year-35.19%USD 27.142023-08-18
5 year-18.7%USD 21.632021-08-20
Since inception+173.76%USD 6.172011-11-14

Daiichi Sankyo, Financials at a Glance

Market Cap

$30.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.26T

Net Income (TTM)

¥247.05B

EPS (TTM)

$0.85

P/E Ratio

19.77

Dividend

$0.49

Beta (Volatility)

0.57 (Low)

Price

$17.59

Volume

150,323

Open

$17.38

Previous Close

$17.59

Daily Range

$17.37 - $17.61

52-Week Range

$14.98 - $27.50

Estimated Earnings Date

Oct 30, 2026

DSNKY News

Female scientist with pipette in lab

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Keith SpeightsJun 12, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Daiichi Sankyo,

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Industry

Pharmaceuticals

Sector

Health Care

Employees

20,171

CEO

Hiroyuki Okuzawa

Website

www.daiichisankyo.co.jp

Headquarters

Tokyo, TY 103-8426, JP

DSNKY Financials

Key Financial Metrics (TTM)

Gross Margin

68.47%

Operating Margin

8.83%

Net Income Margin

10.93%

Return on Equity

14.44%

Return on Capital

11.14%

Return on Assets

5.91%

Earnings Yield

5.06%

Dividend Yield

2.91%

Payout Ratio

59.07%

Stock Overview

Market Cap

$30.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.82B

Volume

150.32K

Avg. Volume

263.47K

Financials (TTM)

Gross Profit

¥1.55T

Operating Income

¥199.48B

EBITDA

¥315.94B

Operating Cash Flow

¥140.93B

Capital Expenditure

-¥138.41B

Free Cash Flow

¥2.52B

Cash & ST Invst.

¥633.64B

Total Debt

¥497.18B

Daiichi Sankyo, Performance Analysis

Daiichi Sankyo, annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 9,437,849,0681.5%
20242024-03-31JPY 11,090,991,16917.5%
20252025-03-31JPY 12,372,918,73811.6%
20262026-03-31JPY 14,088,629,81013.9%
Daiichi Sankyo, sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-307.4%
Q32025-12-3111.5%
Q42026-03-315.7%
Q12026-06-30-3.0%
Daiichi Sankyo, annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.4235.2%
20242024-03-31JPY 0.7272.5%
20252025-03-31JPY 1.0241.1%
20262026-03-31JPY 0.93-8.9%
Daiichi Sankyo, sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-45.9%
Q32025-12-3191.1%
Q42026-03-31-49.6%
Q12026-06-3061.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥582.31B

+22.7%

Gross Profit

¥456.38B

+19.4%

Gross Margin

78.37%

N/A

Market Cap

$30.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.52M

N/A

Employees

20,171

N/A

Net Income

¥69.54B

-18.7%

EBITDA

¥107.92B

-5.8%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥633.64B

+10.3%

Total Debt

¥497.18B

+147.1%

Accounts Receivable

¥672.45B

+9.9%

Inventory

¥728.21B

+29.1%

Long Term Debt

¥496.70B

+392.6%

Short Term Debt

¥474.84M

-99.5%

Return on Assets

5.91%

N/A

Return on Invested Capital

5.86%

N/A

Free Cash Flow

-¥17.13B

+73.8%

Operating Cash Flow

¥20.60B

+156.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLNCFHaleon plc
$4.83+0.21%
UCBJYUCB S.A.
$128.04+1.62%
UCBJFUCB S.A.
$261.34+2.65%
LZAGFLonza Group AG
$729.65+3.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
MRNAModerna
$174.38+1.77%
BITOProShares Trust - ProShares Bitcoin ETF
$9.25+0.06%
IBITiShares Bitcoin Trust
$38.78+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.19+0.08%

Questions About DSNKY

What is the current price of Daiichi Sankyo,?

Daiichi Sankyo, is trading at $17.59 per share.

What is the 52-week range for Daiichi Sankyo,?

Over the past 52 weeks, Daiichi Sankyo, has traded between $14.98 and $27.50.

How much debt does Daiichi Sankyo, have?

As of the most recent reporting period, Daiichi Sankyo, reported total debt of ¥3.08B.

How much cash does Daiichi Sankyo, have on hand?

Daiichi Sankyo, reported ¥3.92B in cash and cash equivalents in its most recent financial results.

What is Daiichi Sankyo,’s dividend yield?

Daiichi Sankyo, currently has a dividend yield of 2.91%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services